/

|

Eli Lilly will invest tens of billions more dollars on U.S. drug manufacturing in a significant enlargement of plans the Indianapolis company had already described as historic.

Lilly, which makes the popular obesity medicine Zepbound, previously pledged to spend $23 billion on constructing and refurbishing factories in the U.S. to churn out the company’s new pills and injections. On Tuesday, the company more than doubled that target. Including commitments made since 2020, it expects to pour over $50 billion into U.S. capital expenditures.